1. Serum IL‑21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
   Yue Li et al, 2021, Experimental and Therapeutic Medicine CrossRef
2. Cytokine profiles and virological markers highlight distinctive immune statuses, and effectivenesses and limitations of NAs across different courses of chronic HBV infection
   Lixin Xiao et al, 2024, Cytokine CrossRef
3. Identification of the novel 3′ UTR sequences of human IL-21 mRNA as potential targets of miRNAs
   Yutaka Enomoto et al, 2017, Scientific Reports CrossRef
4. NAFLD and HBV interplay - related mechanisms underlying liver disease progression
   Evanthia Tourkochristou et al, 2022, Frontiers in Immunology CrossRef
5. Elevation of BSF-2 Level in Serum of Patients with Hepatitis B Virus
   Ali A. Dawood et al, 2021, Medical Immunology (Russia) CrossRef
6. Interleukin-21 Is Associated with Early Antiviral Response in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease
   Xudong Liu et al, 2016, Journal of Interferon & Cytokine Research CrossRef
7. Cytokines and Chemokines in HBV Infection
   Shihong Zhong et al, 2021, Frontiers in Molecular Biosciences CrossRef
8. Elevated serum A20 is associated with severity of chronic hepatitis B and A20 inhibits NF-κB-mediated inflammatory response
   Hanchen Xu et al, 2017, Oncotarget CrossRef
9. Serum Interleukins as Potential Prognostic Biomarkers in HBV-Related Acute-on-Chronic Liver Failure
   Lili Zhang et al, 2022, Mediators of Inflammation CrossRef